QNRX Quoin Pharmaceuticals
- 0.7300
- +0.0198+2.79%
- 0.7300
- 0.00000.00%
Quoin Pharmaceuticals News
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today
Quoin Pharmaceuticals Is Maintained at Buy by Maxim Group
Quoin Pharmaceuticals Is Maintained at Buy by Maxim Group
Express News | Maxim Group Maintains Buy on Quoin Pharmaceuticals, Lowers Price Target to $4
Quoin Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 327.76% Maxim Group $15 → $4 Maintains Buy 09/07/2022 2038.81% Alliance Global Partners → $20 I
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript
Earnings Call: Quoin Pharmaceuticals Reports Q4 Progress and Outlook
Earnings Call Summary | Quoin Pharmaceuticals(QNRX.US) Q4 2023 Earnings Conference
The following is a summary of the Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript:Financial Performance:Quoin Pharmaceuticals Ltd ended the year with around $10.7 million cash and
Quoin Pharmaceuticals: Q4 Earnings Insights
Quoin Pharmaceuticals (NASDAQ:QNRX) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsQuoin Pharmaceuticals be
Quoin Pharmaceuticals Q4 2023 GAAP EPS $(2.08) Beats $(2.31) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(2.08) per share which beat the analyst consensus estimate of $(2.31) by 9.96 percent.
Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results Company reported positive initial clinical data for QRX003 from first six evaluable subjects in
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. • Silence Therapeutics (NASDAQ:SLN) is expec
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical
Preview: Quoin Pharmaceuticals's Earnings
Quoin Pharmaceuticals (NASDAQ:QNRX) is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Here's what investors need to know before the announcement.Analysts estimate that Quoi
Samsara, DocuSign, Gap Among Premarket Gainers' Pack
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAinos (NASDAQ:AIMD) shares increased by 144.6% to $2.74 during Friday's pre-market session. The company's market cap stands at $12.8 million. Psyence Biomedical (NASDAQ:PBM) stock moved upwards
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to Be Held on Thursday March 14th at 8:30 Am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan di
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%
This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed lower on Tuesday as the S&P/BNY Mellon index
Top Midday Decliners
Quoin Pharmaceuticals (QNRX) shares slumped 42% amid heavy trading after the company said on Tuesday it priced a $6.5 million offering of American depositary shares and warrants. More than 3.41 millio
EYEN, BYSI and FENG Among Mid-day Movers
Quoin Stock Craters 47% on Public Offering After Rallying in Prior Session
Analysis
Price Target
No Data
